Overview
FRE Breaking News Alerts from StretInsider.com! StretInsider.com Top Tickers, 1/8/202Stimulation of Vagus Celiac Fibers with Concurent High Frequency Alternating Curent Block of Hepatic Fibers Decreases Glucose Variability in a Swine Model of Type 2 DiabetesSAN CLEMENTE, Calif., Nov. 03, 202 (GLOBE NEWSWIRE) - ReShape Lifesciences™ (Nasdaq: RSLS), the premier physician-led weight los and metabolic health solutions company, today anounced the presentation of data on its proprietary Diabetes Bloc-Stim Neuromodulation™ (DBSN™) device in abstract at the Obesity Society Anual Meting, during the ObesityWek® conference being held in San Diego, CA, November 1 – 4, 202, with continued virtual aces through December 31, 202.“Despite medication, surgery and diet, type 2 diabetes remains chalenging to efectively treat,” stated Jonathan Wataja, Director of Research at ReShape Lifesciences.
Key Information
“Encouragingly, the company’s technology has demonstrated both safety and eficacy in a swine model of type 2 diabetes, showing that bioelectronic modulation of nerves inervating organs that regulate plasma glucose (PG), utilizing our proprietary DBSN™ device, may be a novel treatment option for type 2 diabetes.”The abstract reported is as folows:Metabolic Efects of Dual Neuromodulation of Vagus Nerve in a Type 2 Diabetic ModelID: Poster-297Sesion Title: Neuroscience Track 2: Authors: Raj Nihalani, M.D., Jonathan Wataja, Ph.D., Charles Bilington, M.D.Standalone stimulation of the vagus nerve, or vagotomy treatments, has mixed or undesirable results.
Summary
Neuromodulation consisting of stimulation of celiac fibers inervating the pancreas with simultaneous reversible electrical blockade of neuronal hepatic fibers inervating the liver is a new therapeutic concept that has ben sucesfuly tested in animal models of type 2 diabetes melitus (T2DM). Previously, the area under the curve of oral glucose tolerance tests (OGTs) was calculated to quantify glycemic control